Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04419909 · ClinicalTrials.gov registry record · Phase 1
Retreatment With CTL019/CTL119
A Phase 1 study, sponsored by University of Pennsylvania.
- Not yet
- Registry status
- Phase 1
- Development phase
- 12
- Enrollment target
NCT04419909: Clinical Trial Phase 1 study, sponsored by University of Pennsylvania.
NCT04419909 is a Phase 1 study that has not yet begun recruiting, run by University of Pennsylvania. The registered enrollment target is 12 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04419909, a Phase 1 study, has not yet begun recruiting, sponsored by University of Pennsylvania.
- NOT YET RECRUITING
- Registry status
- Phase 1
- Development phase
- 12 participants
- Enrollment target
Study Summary
This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.
Interventions
- DRUG CD19 redirected autologous T cells (CTL019 or CTL119 cells)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2026-05 |
| Est. Completion | 2028-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04419909
The ClinicalTrials.gov registry entry for NCT04419909 describes a study currently listed as not yet recruiting, categorized as Phase 1. The registered enrollment target is 12 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Pennsylvania, which has 1,423 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which CD19 redirected autologous T cells (CTL019 or CTL119 cells) is the first listed.
NCT04419909 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04419909 about?
NCT04419909 is a clinical study titled "Retreatment With CTL019/CTL119". This research study is designed to evaluate the effects of retreatment with CTL019/CTL119 in patients with late relapse of B-cell lymphomas.
What is the current status of trial NCT04419909?
This trial is currently not yet recruiting. It is a Phase 1 study. The enrollment target is 12 participants. The study started on 2026-05. Estimated completion is 2028-07.
What interventions are being tested in trial NCT04419909?
The interventions under investigation include: CD19 redirected autologous T cells (CTL019 or CTL119 cells) (DRUG).
Who is sponsoring clinical trial NCT04419909?
This trial is sponsored by University of Pennsylvania, which has 1,423 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.